Lung and breast cancer, survival increases with new drugs

New advances in therapies for the treatment of lung and breast cancer. As for concerns small cell lung cancer in the early stages extended, pharmaceutical company Roche announced the results of the phase III IMforte study of atezolizumab in combination with lurbinectedin as maintenance treatment in the first line, after induction therapy with carboplatin, etoposide and atezolizumab. The data showed that this combination reduced the risk of disease progression or death of 46% and the risk of death of 27%, compared to therapy alone maintenance with atezolizumab. Important progress in the fight to a pathology that is already found in the extensive stage in 70% of cases of cases and for which only one patient in five survives for more than of two years. As for breast cancer, in the results Roche presents final results of survival analysis global results of the phase III Inavo120 study, it emerged as inavolisib in combination with palbociclib and fulvestrant increases life expectancy in patients by more than 30% compared to to the combination of palbociclib and fulvestrant. Specifically, The median overall survival was 34.0 months for patients in the inavolisib arm, compared to 27.0 months in the palbociclib and fulvestrant. In addition, the regimen based on inavolisib also demonstrated an improvement in the rate of objective response (the percentage of patients in whom the cancer disappears completely or is significantly reduced) and the exploratory analyses conducted have shown that it is capable of substantially extend free time from chemotherapy for about two years.